Wednesday, July 28, 2021

Diabetes cure: USFDA approves Biocon#39;s long-acting insulin Semglee as first interchangeable biosimilar product

Diabetes cure: USFDA approves Biocon#39;s long-acting insulin Semglee as first interchangeable biosimilar product Diabetes cure: USFDA’s designation of Semglee (insulin glargine) as interchangeable with Lantus (insulin glargine of Sanofi) means that Semglee may now be substituted for the reference product at the pharmacy without the intervention of the prescriber.

from Moneycontrol Business News https://ift.tt/3f9mtIh
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Largecap valuations near fair value, time to start deploying: Jyotivardhan Jaipuria

​So, banks are cheap. And second is, at these valuations, a lot of bad news is priced in. So, as we see growth coming back, as we see things...